Merck & Co., Inc. vs MannKind Corporation: SG&A Expense Trends

SG&A Expense Trends: Merck & Co., Inc. vs MannKind Corporation

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. Over the past decade, from 2014 to 2023, Merck & Co., Inc. and MannKind Corporation have shown distinct patterns in their Selling, General, and Administrative (SG&A) expenses. Merck, a global leader, consistently reported SG&A expenses averaging around $10 billion annually, with a slight decline of approximately 5% from 2014 to 2020, followed by a recovery trend. In contrast, MannKind, a smaller player, exhibited more volatility, with expenses ranging from $47 million to $108 million, peaking in 2015. This disparity highlights the scale and operational differences between the two companies. While Merck's expenses reflect its expansive operations, MannKind's fluctuations may indicate strategic shifts or market challenges. These insights provide a window into the financial strategies and market positioning of these pharmaceutical giants.